Tipifarnib lives!!
#ASCO17 #HRAS #KRAS twitter.com/tomsilver39/status/87252...
0
0
0
0
Hashtag
#ASCO17
Advertisement · 728 × 90
Congrats, @mtmdphd - you helped put together a great #ASCO17.
0
0
0
0
What MDs are NOT buzzing about from #ASCO17: cookies, ads, and pamphlets. Try again, WaPo! http://wapo.st/2qZqQts?tid=ss_tw&utm_term=.27968d601564
0
0
0
0
0
0
0
0
Wait ... what is this? This is not Chen and Melman cycle picture. I am confused and lost. #Asco17 #nobingo
0
0
0
0
0
0
0
0
Congrats to my good friend Keith Orford & the great team at $CALA on their Ph1 data for their CB-1158 arginase inhibitor! @KWOrford #ASCO17
0
0
0
0
L. Fong & $CRVS did a nice job bird-dogging pre-rx scans to show change in rate of growth over time. Harder to do than you think! #ASCO17
0
0
0
0
I wonder if the Roche CEA-TCB bispecific would do better if given before pts got 3 lines of chemo. Should do a neoadj window study. #ASCO17.
0
0
0
0
Tolcher: “It’s the single most important single agent in the treatment of urothelial cancer.” #ASCO17
0
0
0
0
I’m expecting Tolcher’s comments on efortumab vedotin to be very favorable, given the way he’s set up his talk. #ASCO17
0
0
0
0
Tolcher: far more impressed with DS-8201a activity, esp within HER2+ breast and especially gastric. #ASCO17
0
0
0
0
Past performance predicts future ADCs - Tolcher cites vindesine (1980s) as predicting lack of efficacy for MMAE ADCs in melanoma. #ASCO17
0
0
0
0
Tolcher not smiling upon gpNMB ADC data: “10% is borderline for any new therapy, only 1 CR”. #ASCO17
1
0
0
0
Tony Tolcher (START) and his bar for ADCs: “In patients selected for high target tumor antigen expression, CRs must be observed.” #ASCO17
0
0
0
0
Would be great, in this era, to move away from “smart bomb” descriptor for ADCs. It makes me think of horror of war vs curing pts. #ASCO17
0
0
0
0
Is the subtext her that the # of combinatorial possibilities within I-O are enough to make anyone cry?
#ASCO17 #nottheonion https://twitter.com/gulleyj1/status/871198049992880128
0
0
0
0
Combo of enfortumab vedotin with at checkpoint in bladder cancer seems low hanging fruit. Hope they get that trial started soon! #ASCO17
0
0
0
0
Great review on ADC technology in the clinic by @BurrisSkip to open the session at #ASCO17. Huge portfolio of trials at @SarahCannonDocs.
0
0
0
0
CC: @Converse - official shoes of biotech journalists at #ASCO17 https://twitter.com/drsam/status/871736777454780420
0
0
0
0
0
0
0
0
Me and my fellow members of the tribe want to amend #RECIST to include a new endpoint: CR, PR, SD, PD, & "Vell, it could be woise!" #ASCO17
0
0
0
0
MONALEESA2: good results (at 24 mo PFS 54% w/ ribociclib). 68% req dose ⬇️. @hoperugo should we use lower doses in CTs, not P2 max? #ASCO17
0
0
0
0
Anticipating some great music with @ScottDulitz at the #SusanGKomen gathering at @HOBChicago rounding out #ASCO17
0
0
0
0
@METUPorg #ASCO17
Just tracking symptoms & reporting to care team improves survival by 5 mo.
http://meetinglibrary.asco.org/record/147027/abstract
0
0
0
0
Hall D1 at #ASCO17: GITR-up!
GITR done!
(Yee haw!)
0
0
0
0
With all the crap news today, the one shining point is that nobody has used #comicsans in any talk I've been to at #asco17 (so far).
0
0
0
0
It's nice to see the CAR-T+pembro data, but a review of 5 cases is #anecdata, and not a great scientific talk. #ASCO17
0
0
0
0
The latest Leisure Letter! paper.li/LaQuishaR/1342354430 Thanks to @Unity_Coach @robotbum @egapnala65 #wonderwoman #asco17
0
0
0
0